Even most of the folks described in the article did not have an initial reaction of "It only costs a fraction of existing methods!" Instead, their reaction was that the price was set by forces that had nothing to do with the R&D of the drug, and by that measure, it costs far much more that it otherwise could be. When the patent expires, a generic alternative will likely be made for far cheaper.